The partners aim to identify a microRNA-based signature that can predict lung cancer patient response to Bristol-Myers Squibb's immunotherapy Opdivo.
The assay, which was initially approved in June 2015, can now be used on an automated slide stainer which the company said is used in labs all over the world.
N-of-One will provide treatment strategies and clinical trial opportunities for patients based on Inivata's ctDNA liquid biopsy test.
The company said Humana, Medical Mutual of Ohio, and PreferredOne will now cover the non-small cell lung cancer test for their 11.5 million members.
In Science this week: tissue of origin affects cancer cell activity, and more.
If validated further, the 14-gene predictor — associated with aberrant cell division and genome instability — could help avoid overtreatment in low-risk patients, as well as identify those who will respond well to chemotherapy and radiation.
The gene expression assay, which targets 18 markers, is being used by Merck in three new Phase III clinical trials to expand the indication for Keytruda.
The company credited the increased revenues to a 12 percent rise in the number of Oncotype Dx tests delivered.
Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.
Horizon BCBS of New Jersey, which covers 3.8 million people in that state, began covering the test for patients with non-small cell lung cancer on May 10, 2016.
In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.
Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.
The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.
Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.